• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
Vaccine. 2022 Jun 14:S0264-410X(22)00755-1. doi: 10.1016/j.vaccine.2022.06.008. Online ahead of print.ABSTRACTReplication-deficient adenoviral vectors have been under investigation as a platform technology for vaccine development for several years and have recently been successfully deployed as an effective COVID-19 counter measure. A replication-deficient adenoviral vector based on the simian adenovirus type Y25 and named ChAdOx1 has been evaluated in several clinical trials since 2012. The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) was formed to evaluate the safety and other key fe...
Source: Vaccine - June 17, 2022 Category: Allergy & Immunology Authors: Pedro M Folegatti Daniel Jenkin Susan Morris Sarah Gilbert Denny Kim James S Robertson Emily R Smith Emalee Martin Marc Gurwith Robert T Chen Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO, ex-V3SWG) Source Type: research

Travel vaccines are strongly associated to reduced mortality in prostate cancer patients - a real effect or residual confounding?
Vaccine. 2022 May 21:S0264-410X(22)00611-9. doi: 10.1016/j.vaccine.2022.05.028. Online ahead of print.ABSTRACTRepurposing of existing drugs and vaccines for diseases that they were not originally intended for is a promising research field. Recently there has been evidence that oral cholera vaccine might be used in the treatment of inflammatory disease and some common cancers. Specifically, Ji et al showed that the administration of cholera vaccine after a prostate cancer diagnosis reduced prostate cancer specific mortality rates by almost 50%. In a cohort of men from Stockholm, Sweden, with more detailed cancer data and a ...
Source: Vaccine - May 24, 2022 Category: Allergy & Immunology Authors: Axel M öller Klaus Schwamborn Adrian Spillmann Janet Hoogstraate Robert Szulkin Olof Akre Lars Egevad Mark Clements Markus Aly Source Type: research

From “Serum Sickness” to “Xenosialitis”: Past, Present, and Future Significance of the Non-human Sialic Acid Neu5Gc
Conclusions and Perspectives In this review, we have discussed important milestones from the early description of “Serum-sickness” as being due to antibodies directed against Neu5Gc epitopes all the way to the present-day therapeutic implications of these antibodies in cancer therapy. Some of these milestones have been represented in a concise timeline (Figure 6). While the “Xenosialitis” hypothesis is well-supported in the human-like mouse models, it has yet to be conclusively proven in humans. It remains to be seen if “Xenosialitis” plays a role in other uniquely-human dis...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

Fight Aging! Newsletter, January 28th 2019
In this study, we show that calorie restriction is protective against age-related increases in senescence and microglia activation and pro-inflammatory cytokine expression in an animal model of aging. Further, these protective effects mitigated age-related decline in neuroblast and neuronal production, and enhanced olfactory memory performance, a behavioral index of neurogenesis in the SVZ. Our results support the concept that calorie restriction might be an effective anti-aging intervention in the context of healthy brain aging. Greater Modest Activity in Late Life Correlates with Lower Incidence of Dementia ...
Source: Fight Aging! - January 27, 2019 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs